Immunic (IMUX)
(Delayed Data from NSDQ)
$1.27 USD
+0.03 (2.42%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $1.26 -0.01 (-0.79%) 5:08 PM ET
3-Hold of 5 3
F Value B Growth A Momentum D VGM
Brokerage Reports
Immunic, Inc. [IMUX]
Reports for Purchase
Showing records 201 - 213 ( 213 total )
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
A Diamond in the Rough for MS - COVID - Best Idea Stock in 3Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
After Today''s R-D Day, Do Not Miss Our 3-Part Call Series Starting May 29
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-838 Clearance From German Regulators for COVID-19 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
One Good Turn Deserves Another; Do Not Miss Our 3-Part Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline in a Pill, With a Possible COVID-19 Cherry Atop the Cake; Initiating at Buy and $45 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 - IMUX-838 Burns Midnight Oil in COVID-19 - MS - Must Read
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMUX-838 Surprises Us with Anti-Viral Activity Against SARS-CoV-2
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Your Twin IMU-838 Is Better Looking in MS; Initiating with Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
We are sending out a reminder about our 33rd Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department